organization

de Duve Institute

DE DUVE INSTITUTE AISBL
6 projects, page 1 of 2
  • project . 2018 - 2022
    Funder: EC Project Code: 800981
    Overall Budget: 3,000,000 EURFunder Contribution: 3,000,000 EUR
    Open Access mandate for Publications and Research Data
    Partners: KCL, POIETIS, Technion – Israel Institute of Technology, de Duve Institute, ETH Zurich, TAU

    Developing therapies for pancreatic diseases, such as diabetes and pancreatic cancer, is hampered by a limited access to pancreatic tissue in vivo. Engineering three-dimensional (3D) tissue models, which accurately mimic the native organ, have great potential in biomedi...

  • project . 2021 - 2025
    Funder: EC Project Code: 964955
    Overall Budget: 3,998,660 EURFunder Contribution: 3,998,660 EUR
    Open Access mandate for Publications and Research Data
    Partners: STIFTUNG REGENSBURGER CENTRUM FUR INTERVENTIONELLE IMMUNOLOGIE, San Raffaele Hospital, MUI, de Duve Institute, BCC, TUW, UPNANO GMBH, NTNU

    Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Without breakthroughs in treatment, cancer is likely to remain one of the biggest killers in the 21st century. Immunotherapy of cancer ...

  • project . 2019 - 2023
    Funder: EC Project Code: 814316
    Overall Budget: 3,792,140 EURFunder Contribution: 3,792,140 EUR
    Open Access mandate for Publications and Research Data
    Partners: MPG, INSERM, FINNADVANCE, UTA, Uppsala University, UP, KI, University of Oulu, de Duve Institute, AstraZeneca (Sweden)

    Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, and for which effective treatments are lacking. The European V.A. Cure network aims to address this unmet medica...

  • project . 2020 - 2025
    Funder: EC Project Code: 874708
    Overall Budget: 8,064,950 EURFunder Contribution: 8,064,950 EUR
    Open Access mandate for Publications and Research Data
    Partners: INSERM, Charles University, University of Liège, Uppsala University, CNRS, de Duve Institute, Centre Hospitalier Universitaire de Toulouse, FLASH THERAPEUTICS, Inserm Transfert, HELSINGIN YLIOPISTO...

    Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg. It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide. It is handicapping, painful and impacts substant...

  • project . 2018 - 2022
    Funder: EC Project Code: 754688
    Overall Budget: 5,949,960 EURFunder Contribution: 5,949,960 EUR
    Open Access mandate for Publications and Research Data
    Partners: Charité - University Medicine Berlin, SYSBIOSIM BV, Durham University, Stiftung PATH Biobank, University Hospital Heidelberg, Universität Innsbruck, UNEW, GERMAN CANCER RESEARCH CENTER, de Duve Institute, VHIO...

    Breast cancer (BC) is a complex disease with high prevalence in the EU. 75% of the tumors are estrogen receptor-positive (ER+), and are treated with endocrine therapies (ET). MESI-STRAT will develop new concepts for knowledge-based stratification of patients into subgro...

6 projects, page 1 of 2
Any information missing or wrong?Report an Issue